Clinical trials: Chronic Obstructive Pulmonary Diseases
Ischemic Motor Stroke, Chronic
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
The study is to determine the safety of human neural stem cell transplantation for the treatment of paralysis and related symptoms due to chronic motor stroke and to determine the maximum tolerated dose.
- Trial name
- NCT03296618
- Testing
- NSI-566
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Neuralstem Biopharmaceuticals
Healthy, Lupus
Direct to Patient Minimal Risk Biospecimen and Data Collection Research
This study aims to help researchers better understand health conditions and develop improved tests, treatments, and cures for diseases.
- Conditions
- Healthy, Lupus, Celiac, Kidney Disease
- Trial name
- JBMR (NCT07128966)
- Testing
- Observation
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Joined Bio
COPD
Loop Band Validation Study
The main purpose of this study is to assess the accuracy of a non-invasive wearable technology in the form of a wristband.
- Trial name
- NCT03240926
- Testing
- Loop Band
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Spry Health
Chronic Obstructive Pulmonary Disease (COPD)
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)
This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F…
- Trial name
- NCT00383435
- Testing
- Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI
- Volunteers
- 1,055 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
The objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive…
- Trial name
- NCT00157235
- Testing
- Tiotropium bromide
- Where
- 12 sites in Italy
- Volunteers
- 234 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow…
- Trial name
- NCT04223843
- Testing
- Tiotropium + olodaterol
- Where
- 26 sites in United States, Germany
- Volunteers
- 213 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status.
- Trial name
- NCT00239408
- Testing
- Pulmonary function Testing, tiotropium bromide
- Where
- 33 sites in Portugal
- Volunteers
- 311 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging
In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging.
- Trial name
- NCT02451540
- Testing
- HRCT scan, Roflumilast
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- FLUIDDA nv
COPD
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD patients. Part 2 was an efficacy study in GOLD I-III COPD patients.
- Trial name
- NCT01972776
- Testing
- QBM076
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT05638776
- Testing
- REGEND001 cell therapy
- Where
- 8 sites in China
- Volunteers
- 58 people
- Sponsor
- Regend Therapeutics
Pulmonary Disease, Chronic Obstructive, COPD
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Researchers are looking for new ways to treat chronic obstructive pulmonary disease (COPD). COPD is a long-lasting swelling of the airways that makes it hard to breathe.
- Trial name
- NCT05270525
- Testing
- Ensifentrine, LABA/LAMA
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- OBERON (NCT05166889)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Argentina and 19 more
- Volunteers
- 1,132 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to identify demographic and non-spirometric clinical features predictive of the asthma-COPD overlap population.
- Trial name
- NCT02302417
- Testing
- Spirometry, ACOS clinical questionnaire
- Where
- 42 sites in United States, Argentina and 3 more
- Volunteers
- 1,215 people
- Sponsor
- GlaxoSmithKline
Asthma, COPD
An Open Study to Assess the Robustness of the CRC749 Inhaler
To confirm the robustness of the CRC749 inhaler.
- Trial name
- NCT02474017
- Testing
- MGR001, CRC749 inhaler
- Where
- 2 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Mylan Pharma UK Ltd.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD
This efficacy and safety study compares four different combinations of blinded inhaled steroid treatments on top of open-label tiotropium and salmeterol in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00535366
- Testing
- Tiotropium, Salmeterol, Fluticasone
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
Constipation
A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation
Constipation is common in the general population, especially in women and in the elderly. Hard stool is a complaint often associated with constipation, which suggests that stool softening would provide a major benefit in the…
- Trial name
- NCT02073006
- Testing
- Natural Fibre Supplement
- Where
- Ireland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma
- Trial name
- NCT00152984
- Testing
- Tiotropium inhalation capsules
- Where
- 68 sites in Belgium, Canada and 6 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD.
- Trial name
- NCT01437878
- Testing
- Iloprost
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Actelion
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01017952
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 183 sites in United States, Argentina and 13 more
- Volunteers
- 1,635 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
- Trial name
- NCT00345774
- Testing
- PRX-08066
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Epix Pharmaceuticals, Inc.